News

A new report sheds light on how ACA enrollment fared in 2019, and what insurers are thinking about the future.

The chain’s move is an attempt to increase relationships with traditionally-loyal pharmacy patients.

With worsening storms and other natural disasters, it’s more important than ever for healthcare executives to pay attention to emergency power supplies.

Joan Budden has created a culture at Priority Health, the No. 2 health insurer in Michigan, that encourages and rewards innovative thinking.

What UCLA Health’s partnership with Microsoft means.

Managed Healthcare Executive’s Managed Care Pharmacy Survey identifies different ways specialty pharmacy stakeholders believe they can reduce industry costs moving forward.

As CBD, or cannabidiol, surges in popularity, the FDA held its first public hearing on the chemical that claims to help with a variety of ailments including pain and anxiety.

A new survey shows that while many healthcare executives recognize drug diversion as a problem, few admit to it happening in their organization.

A new NIH report on cancer in people aged 20 to 49 shows that while rates are declining, women and minorities still face significant rates.

In the three decades since its passage, Stark Law has become one of the most significant sources of regulatory burden on physicians and, ultimately, for Medicare beneficiaries.

FDA cleared alpelisib (Piqray), the first PI3K inhibitor to treat breast cancer, to be used in combination with fulvestrant (Faslodex).

FDA granted market authorization for a non-invasive, smartphone device that offers respite from migraines.

New study compares every state using data like opioid prescriptions and overdose rates to determine where drug problems hit hardest.

From drug price concerns to the evolving role of PBMs to the influence of specialty pharmaceuticals, what healthcare executives think about the future of pharmacy.

Here are five surprising ways to tailor experiences so patients adopt healthier behaviors when faced with chronic conditions like diabetes, heart disease, cancer, and COPD.

How will payers, providers, and patients respond when a $2 million drug drops into the market?

The 2018 oncology drug market had a record number of new treatments and continued a trend of growth.

A new report shows that the new open enrollment rules are leading to increased Medicare Advantage uptake.

Healthcare costs remain the most important financial problem facing American families, according to a Gallup poll.

The prevalence of diagnosed diabetes in the United States has remained stable during the past eight years, even as obesity rates climb.

New definition of burnout to be included in forthcoming ICD-11.

As Best Buy extends its reach into health technologies and services, a unique opportunity may open up for providers.

In the first of many similar cases, the trial of Oklahoma versus Johnson & Johnson could frame who is to blame for the opioid epidemic.

With a more than $2 million price tag, how are payers going to deal with the recently approved Zolgensma?

The new plan could affect all of healthcare and could radically change contract provider agreements. 

What the development means for healthcare.

A majority of healthcare workers are women, but few make it to leadership roles. Here are the surprising reasons behind the gap.

Where plans and patients are spending the most money on medications.